Reuters logo
BRIEF-Otonomy reports results for Averts-1 phase 3 trial for Otividex
August 30, 2017 / 11:28 AM / 3 months ago

BRIEF-Otonomy reports results for Averts-1 phase 3 trial for Otividex

Aug 30 (Reuters) - Otonomy Inc:

* Says ‍company is withdrawing spending guidance for year pending review of product pipeline plans

* Otonomy reports results for Averts-1 phase 3 trial for Otividex in patients with Ménière’s disease

* Says ‍company to immediately suspend all development activities for Otividex​

* Says clinical trial missed its primary endpoint

* Says ‍clinical trial missed its primary endpoint which was count of definitive vertigo days by Poisson Regression analysis​

* Says ‍trial also failed to achieve statistical significance for any of key secondary vertigo endpoints at month 3​

* Says ‍undertaking a review of its product pipeline plans and commercial efforts in order to identify “opportunities” to extend its cash runway​ Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below